New drug combo shows promise for tough cervical cancers
NCT ID NCT07266350
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will observe 1,300 patients with advanced or recurrent cervical cancer who are treated with camrelizumab, famitinib, or combinations of these drugs. The goal is to see how safe and effective these treatments are in real-world settings. Patients are placed into one of six groups based on their treatment plan, and data is collected over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- camrelizumab and famitinib
- What this could lead to
- If successful, this could provide real-world evidence that these drugs are safe and effective for treating advanced or recurrent cervical cancer.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less definitive. The drugs may cause side effects like immune-related reactions or bleeding.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Simple HPV swab or blood test may spot returning cervical cancer earlier
- New hope for advanced cervical cancer: drug combo trial launches
- New combo aims to tame advanced cervical cancer with fewer side effects
- New drug SLV-154 enters human testing for Hard-to-Treat cancers
- New combo therapy shows promise for Hard-to-Treat cervical cancer